Coincident remission of ankylosing spondylitis after autologous stem cell transplantation for multiple myeloma.
Aged
Bortezomib
/ administration & dosage
Dexamethasone
/ administration & dosage
Female
Hematopoietic Stem Cell Transplantation
Humans
Lenalidomide
/ administration & dosage
Melphalan
/ administration & dosage
Multiple Myeloma
/ therapy
Remission Induction
Spondylitis, Ankylosing
/ therapy
Transplantation Conditioning
Transplantation, Autologous
Treatment Outcome
Ankylosing spondylitis
autoimmune disease
autologous hematopoietic stem cell transplant
multiple myeloma
rheumatological disease
Journal
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
ISSN: 1477-092X
Titre abrégé: J Oncol Pharm Pract
Pays: England
ID NLM: 9511372
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
pubmed:
5
6
2020
medline:
27
1
2021
entrez:
5
6
2020
Statut:
ppublish
Résumé
Ankylosing spondylitis is an autoimmune disease with chronic inflammation of the spine and sacroiliac joints that is commonly treated with immunosuppressants including disease-modifying antirheumatic drugs and anti-tumor necrosis factor alpha therapy. A 75-year-old female with active ankylosing spondylitis on treatment with etanercept was referred to us for newly diagnosed IgG kappa free light chain multiple myeloma. After failing induction with revlimid, bortezomib, and dexamethasone, she was initiated on carfilzomib. Following the achievement of adequate response to induction, she underwent an autologous hematopoietic stem cell transplant selected for CD34+ cells with melphalan 200mg/m Although our patient had a coincident and unprecedented resolution of ankylosing spondylitis after receiving the hematopoietic stem cell transplant, this case consolidates the idea of transplant as a potential treatment option for ankylosing spondylitis and other rheumatological conditions.
Identifiants
pubmed: 32493162
doi: 10.1177/1078155220927750
doi:
Substances chimiques
Bortezomib
69G8BD63PP
Dexamethasone
7S5I7G3JQL
Lenalidomide
F0P408N6V4
Melphalan
Q41OR9510P
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM